Meeting
2015 ASCO Annual Meeting
Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
Authors
Tycel Jovelle Phillips
University of Michigan, Ann Arbor, MI
Tycel Jovelle Phillips , Andres Forero-Torres , Taimur Sher , Catherine S. Magid Diefenbach , Moshe Talpaz , Peggy A Scherle , Richard Schaub , Li Zhou , Jennifer Pulini , Lance Leopold , Matthew A. Spear , Paul M. Barr
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01905813
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8520)
DOI
10.1200/jco.2015.33.15_suppl.8520
Abstract #
8520
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
First Author: Andres Forero-Torres
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens
Poster
2022 ASCO Annual Meeting
SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.
First Author: Yuqin Song
Poster
2019 ASCO Annual Meeting
A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B Cell malignancies.
First Author: Lugui Qiu